Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q2 FY25 results · Jul–Sep 2024
Aarti Pharmalabs reported revenue from operations of ₹458.03 crore (up 4.1% from Q2 FY24) and net profit of ₹54.62 crore (up 5.4% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 458.03 | 439.80 | +4.1% | 555.49 | −17.5% |
| Other income | 4.48 | 0.98 | +357.4% | 2.22 | +102.3% |
| Total income | 462.51 | 440.78 | +4.9% | 557.71 | −17.1% |
| Profit before tax | 71.77 | 66.95 | +7.2% | 73.68 | −2.6% |
| Net profit for the period | 54.62 | 51.80 | +5.4% | 55.45 | −1.5% |
| EPS, basic (₹) | 6.03 | 5.72 | +5.4% | 6.12 | −1.5% |
| Net margin (%) | 11.9 | 11.8 | 10.0 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 377.29 | 356.14 | +5.9% | 393.49 | −4.1% |
| Other income | 2.95 | 0.00 | — | 2.11 | +39.5% |
| Total income | 380.24 | 356.14 | +6.8% | 395.60 | −3.9% |
| Profit before tax | 63.43 | 53.66 | +18.2% | 63.23 | +0.3% |
| Net profit for the period | 47.84 | 41.18 | +16.2% | 47.14 | +1.5% |
| EPS, basic (₹) | 5.28 | 4.61 | +14.5% | 5.20 | +1.5% |
| Net margin (%) | 12.7 | 11.6 | 12.0 |
Consolidated
- Filed with BSE
- 29 Oct 2024, 13:08 IST
- Board meeting
- 28 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2024, 13:08 IST
- Board meeting
- 28 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Audited
- Source
- XBRL filing on BSE